179 related articles for article (PubMed ID: 38644364)
21. The Use of Methods of Computer-Aided Drug Discovery in the Development of Topoisomerase II Inhibitors: Applications and Future Directions.
Radaeva M; Dong X; Cherkasov A
J Chem Inf Model; 2020 Aug; 60(8):3703-3721. PubMed ID: 32687346
[TBL] [Abstract][Full Text] [Related]
22. Quercetin-3-O-glucoside induces human DNA topoisomerase II inhibition, cell cycle arrest and apoptosis in hepatocellular carcinoma cells.
Sudan S; Rupasinghe HP
Anticancer Res; 2014 Apr; 34(4):1691-9. PubMed ID: 24692698
[TBL] [Abstract][Full Text] [Related]
23. Dual Antibacterial and Anticancer Activity of 4-Benzoyl-1-dichlorobenzoylthiosemicarbazide Derivatives.
Kapron B; Czarnomysy R; Paneth A; Wujec M; Bielawski K; Bielawska A; Swiatek L; Rajtar B; Polz-Dacewicz M; Plech T
Anticancer Agents Med Chem; 2018; 18(4):529-540. PubMed ID: 29065843
[TBL] [Abstract][Full Text] [Related]
24. Low doses of methylnaltrexone inhibits head and neck squamous cell carcinoma growth in vitro and in vivo by acting on the mu-opioid receptor.
Gorur A; Patiño M; Shi T; Corrales G; Takahashi H; Rangel R; Gleber-Netto FO; Pickering C; Myers JN; Cata JP
J Cell Physiol; 2021 Nov; 236(11):7698-7710. PubMed ID: 34038587
[TBL] [Abstract][Full Text] [Related]
25. Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells.
Pan X; Hartley JM; Hartley JA; White KN; Wang Z; Bligh SW
Phytomedicine; 2012 May; 19(7):618-24. PubMed ID: 22402246
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of substituted 9-aminoacridine derivatives in small cell lung cancer.
Ryan E; Blake AJ; Benoit A; David MF; Robert AK
Invest New Drugs; 2013 Apr; 31(2):285-92. PubMed ID: 22821172
[TBL] [Abstract][Full Text] [Related]
27. Relationship of mRNA expressions of RanBP2 and topoisomerase II isoforms to cytotoxicity of amrubicin in human lung cancer cell lines.
Horio Y; Osada H; Shimizu J; Ogawa S; Hida T; Sekido Y
Cancer Chemother Pharmacol; 2010 Jul; 66(2):237-43. PubMed ID: 19809814
[TBL] [Abstract][Full Text] [Related]
28. Effect of extracellular magnesium on topoisomerase II activity and expression in human leukemia HL-60 cells.
Covacci V; Bruzzese N; Sgambato A; Ganapathi R; Cittadini A; Wolf FI
J Cell Biochem; 2000 May; 78(2):325-33. PubMed ID: 10842326
[TBL] [Abstract][Full Text] [Related]
29. DNA topoisomerase II alpha and Ki-67 in human adrenocortical neoplasms: a possible marker of differentiation between adenomas and carcinomas.
Iino K; Sasano H; Yabuki N; Oki Y; Kikuchi A; Yoshimi T; Nagura H
Mod Pathol; 1997 Sep; 10(9):901-7. PubMed ID: 9310953
[TBL] [Abstract][Full Text] [Related]
30. Modification of topoisomerases in mammospheres derived from breast cancer cell line: clinical implications for combined treatments with tyrosine kinase inhibitors.
Peleg R; Romzova M; Kogan-Zviagin I; Apte RN; Priel E
BMC Cancer; 2014 Dec; 14():910. PubMed ID: 25472619
[TBL] [Abstract][Full Text] [Related]
31. Recent advances in the development of catalytic inhibitors of human DNA topoisomerase IIα as novel anticancer agents.
Pogorelčnik B; Perdih A; Solmajer T
Curr Med Chem; 2013; 20(5):694-709. PubMed ID: 23210851
[TBL] [Abstract][Full Text] [Related]
32. New fused pyrimidine derivatives with anticancer activity: Synthesis, topoisomerase II inhibition, apoptotic inducing activity and molecular modeling study.
Nemr MTM; AboulMagd AM
Bioorg Chem; 2020 Oct; 103():104134. PubMed ID: 32750610
[TBL] [Abstract][Full Text] [Related]
33. Stress-responsive Entamoeba topoisomerase II: a potential antiamoebic target.
Varghese SS; Ghosh SK
FEBS Lett; 2020 Mar; 594(6):1005-1020. PubMed ID: 31724164
[TBL] [Abstract][Full Text] [Related]
34. Topoisomerase II alpha expression in squamous cell carcinomas of the head and neck.
Stathopoulos GP; Kapranos N; Manolopoulos L; Papadimitriou C; Adamopoulos G
Anticancer Res; 2000; 20(1A):177-82. PubMed ID: 10769652
[TBL] [Abstract][Full Text] [Related]
35. Topoisomerase II inhibition suppresses the proliferation of telomerase-negative cancers.
Hsieh MH; Tsai CH; Lin CC; Li TK; Hung TW; Chang LT; Hsin LW; Teng SC
Cell Mol Life Sci; 2015 May; 72(9):1825-37. PubMed ID: 25430478
[TBL] [Abstract][Full Text] [Related]
36. Identification of novel topoisomerase II alpha inhibitors by virtual screening, molecular docking, and bioassay.
Yu C; Hu J; Luyten W; Sun D; Jiang T
Chem Biol Drug Des; 2022 Jan; 99(1):92-102. PubMed ID: 34310071
[TBL] [Abstract][Full Text] [Related]
37. Vandetanib sensitizes head and neck squamous cell carcinoma to photodynamic therapy through modulation of EGFR-dependent DNA repair and the tumour microenvironment.
Chu PL; Shihabuddeen WA; Low KP; Poon DJJ; Ramaswamy B; Liang ZG; Nei WL; Chua KLM; Thong PSP; Soo KC; Yeo ELL; Chua MLK
Photodiagnosis Photodyn Ther; 2019 Sep; 27():367-374. PubMed ID: 31299389
[TBL] [Abstract][Full Text] [Related]
38. Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy.
Park K; Kim J; Lim S; Han S
Eur J Cancer; 2003 Mar; 39(5):631-4. PubMed ID: 12628842
[TBL] [Abstract][Full Text] [Related]
39. Indenoindolone derivatives as topoisomerase II-inhibiting anticancer agents.
Kashyap M; Kandekar S; Baviskar AT; Das D; Preet R; Mohapatra P; Satapathy SR; Siddharth S; Guchhait SK; Kundu CN; Banerjee UC
Bioorg Med Chem Lett; 2013 Feb; 23(4):934-8. PubMed ID: 23321564
[TBL] [Abstract][Full Text] [Related]
40. Topoisomerase II inhibition by the bioactivated benzene metabolite hydroquinone involves multiple mechanisms.
Mondrala S; Eastmond DA
Chem Biol Interact; 2010 Mar; 184(1-2):259-68. PubMed ID: 20034485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
